Kinaxo Biotechnologies said this week it has entered a second collaboration with Takeda Pharmaceutical under which it will apply its quantitative phosphoproteomics platform PhosphoScout to drug development.
The companies' first collaboration, which they signed in 2008, involved use of Kinaxo's KinaTor chemical proteomics technology (GWDN 04/18/2008).
PhosphoScout is an LC-MS/MS based system using strong cationic exchange chromatography in combination with IMAC or TiO2 for phosphopeptide enrichment on the front end and the MaxQuant quantitative proteomics software developed in the lab of Max Planck Institute researcher Matthias Mann.
According to Kinaxo's website, the platform can measure the relative quantity of more than 15,000 phosphorylation sites in a single experiment. The company does its mass spec work on Thermo Fisher Scientific LTQ Orbitrap Velos machines.
In addition to the Takeda collaboration, Kinaxo has struck deals with other global pharma companies including AstraZeneca, Johnson & Johnson, Dalichi-Sankyo, Roche, and Bristol-Myers Squibb.
In February, drug developer Evotec announced it had signed a definitive agreement to purchase Kinaxo for up to €16 million ($22 million) in a cash and stock deal (GWDN 02/09/2011).